Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Fox, Robert J. [1 ]
Chan, Andrew [2 ]
Gold, Ralf [2 ]
Phillips, J. Theodore [3 ]
Selmaj, Krzysztof [4 ]
Zhang, Ray [5 ]
Chang, Ih [5 ]
Prada, Claudia [5 ]
Ray, Soma [5 ]
Mehta, Devangi [5 ]
Taylor, Catherine [5 ]
Marantz, Jing [5 ]
机构：
[1] Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Ruhr Univ, St Josef Hosp, Bochum, Germany
[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[4] Med Univ Lodz, Lodz, Poland
[5] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
107
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [21] Sustained low rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study
    Miller, D.
    Yousry, T.
    Fox, R. J.
    Gold, R.
    Arnold, D. L.
    Potts, J.
    Marantz, J. L.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 550 - 551
  • [22] Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE
    Kappos, Ludwig
    Yousry, Tarek
    Fox, Robert
    Gold, Ralf
    Arnold, Douglas
    Potts, James
    Marantz, Jing
    NEUROLOGY, 2016, 86
  • [23] Characterization of absolute lymphocyte count profiles in MS patients treated with delayed-release dimethyl fumarate: considerations for patient management
    Fox, R. J.
    Chan, A.
    Gold, R.
    Phillips, J. T.
    Selmaj, K.
    Zhang, R.
    Chang, I.
    Novas, M.
    Rana, J.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 289 - 290
  • [24] Characterization of absolute lymphocyte count profiles in MS patients treated with delayed-release dimethyl fumarate: considerations for patient management
    Fox, Robert J.
    Chan, Andrew
    Gold, Ralf
    Phillips, Ted
    Selmaj, Krzysztof
    Zhang, Ray
    Chang, Ih
    Novas, Mark
    Ordonez, Claudia
    Rana, Jitesh
    Marantz, Jing
    NEUROLOGY, 2015, 85 (04) : E48 - E48
  • [25] The effect of delayed-release dimethyl fumarate on lymphocyte subsets and immunoglobulins in patients with relapsing-remitting multiple sclerosis: Interim results of an open-label phase 3 study
    von Hehn, C.
    Mehta, D.
    Prada, C.
    Yang, L.
    Liu, S.
    Ray, S.
    Sheikh, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 416 - 416
  • [26] Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis
    Tsantes, E.
    Curti, E.
    Ferraro, D.
    Lugaresi, A.
    Baldi, E.
    Montepietra, S.
    Immovilli, P.
    Simone, A. M.
    Mancinelli, L.
    Strumia, S.
    Vitetta, F.
    Foschi, M.
    Ferri, C.
    Ferrarini, C.
    Sola, P.
    Granella, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (01) : 269 - 277
  • [27] Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis
    Tsantes, E.
    Curti, E.
    Ferraro, D.
    Lugaresi, A.
    Baldi, E.
    Montepietra, S.
    Immovilli, P.
    Simone, A. M.
    Mancinelli, L.
    Strumia, S.
    Vitetta, F.
    Foschi, M.
    Ferri, C.
    Ferrarini, C.
    Sola, P.
    Granella, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 271 - 272
  • [28] Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
    Viglietta, Vissia
    Miller, David
    Bar-Or, Amit
    Phillips, J. Theodore
    Arnold, Douglas L.
    Selmaj, Krzysztof
    Kita, Mariko
    Hutchinson, Michael
    Yang, Minhua
    Zhang, Ray
    Dawson, Katherine T.
    Sheikh, Sarah I.
    Fox, Robert J.
    Gold, Ralf
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2015, 2 (02): : 103 - 118
  • [29] Delayed-release Dimethyl Fumarate Demonstrates Long-term, Sustained Efficacy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis followed for at least Eight-Years
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Fox, Robert J.
    Yang, Lili
    Taylor, Catherine
    NEUROLOGY, 2018, 90
  • [30] Clinical efficacy of delayed-release dimethyl fumarate in Asian patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
    Hochman, S.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Okwuokeny, M.
    Zhang, A.
    Rana, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E307
12345